Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

Rhea-AI Summary

Sionna Therapeutics (Nasdaq: SION) said management will hold one-on-one investor meetings at the Raymond James 2026 Biotech Innovation Symposium on April 14, 2026. The meetings provide investor access to management to discuss clinical progress in cystic fibrosis programs and corporate strategy.

News Market Reaction – SION

-1.66%

-1.66% Session close to close

In the Apr 7 session, SION declined 1.66%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights continued investor-relations outreach, with management engaging in one-...

Analysis

This announcement highlights continued investor-relations outreach, with management engaging in one-on-one meetings at a major biotech symposium but providing no new clinical or financial data. In context, recent news focused on conferences and a Mar 2, 2026 earnings and pipeline update. Investors may watch upcoming mid-2026 clinical readouts and any use of the $250,000,000 at-the-market program as more material catalysts.

Historical Context

5 past events · Latest: Mar 02 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 02	Earnings and pipeline	Negative	-7.2%	Reported higher net loss and expenses with mid-2026 data timelines.
Feb 23	Investor conferences	Neutral	+1.7%	Announced March 2026 investor fireside chats and webcast availability.
Feb 04	Biotech summit talk	Neutral	-7.1%	Planned presentation at Guggenheim Emerging Outlook: Biotech Summit 2026.
Jan 05	J.P. Morgan conference	Neutral	+4.2%	Presentation at 44th Annual J.P. Morgan Healthcare Conference with webcast.
Nov 24	December conferences	Neutral	+1.6%	Participation in early December 2025 Evercore and Citi healthcare conferences.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows mixed reactions: earnings and some conference announcements were followed by sharp moves in both directions, indicating event headlines alone have not driven consistent price behavior.

Recent Company History

Over the last several months, Sionna has mainly issued conference participation and earnings updates. The Mar 2, 2026 earnings and pipeline update saw a -7.17% move, while several investor conference announcements around Jan–Feb 2026 produced both gains and losses, including moves of -7.12% and +4.18%. Today’s symposium participation continues this pattern of investor-relations focused news without new clinical or financial data.

Key Terms

cystic fibrosis, cftr

2 terms

cystic fibrosis medical

"on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF)"

A genetic disease that causes the body to produce thick, sticky mucus that clogs airways and digestive passages, leading to ongoing lung infections, breathing difficulty, and problems absorbing nutrients. For investors, cystic fibrosis matters because treatments range from symptom management to pricey, targeted drugs that can change patient outcomes; progress in therapies, clinical trial results, regulatory approvals, and reimbursement decisions can significantly affect the commercial value of companies working in this area.

cftr medical

"medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein"

CFTR is a gene that makes a protein acting like a tiny gate in cell membranes to control the flow of salt and water; when the gate works properly it helps keep mucus thin and organs functioning. Investors care because mutations in CFTR drive serious diseases and create demand for diagnostics, drugs and long-term treatment revenue; progress or setbacks in therapies, approvals or patents directly affect company value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in one-on-one investor meetings at the Raymond James 2026 Biotech Innovation Symposium on Tuesday, April 14^th, 2026.

About Sionna Therapeutics 
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which occurs in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For more information about Sionna, visit www.sionnatx.com.

Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Sionna’s Investor Relations website, in addition to following Sionna’s press releases, SEC filings, public conference calls, presentations, and webcasts.

Media Contact
Sarah Spencer
media@sionnatx.com

Investor Contact
Juliet Labadorf
ir@sionnatx.com

FAQ

When will Sionna Therapeutics (SION) meet investors at Raymond James 2026?

Sionna will meet investors on April 14, 2026 at the Raymond James symposium. According to the company, management will participate in one-on-one investor meetings to discuss clinical programs and corporate strategy for cystic fibrosis therapeutics.

How can investors request a one-on-one meeting with Sionna Therapeutics (SION) at the conference?

Investors should contact Raymond James or Sionna's investor relations to request meetings ahead of April 14, 2026. According to the company, management will be available for scheduled one-on-one investor meetings during the symposium.

What topics will Sionna Therapeutics (SION) likely cover in April 14, 2026 meetings?

Meetings will focus on Sionna's clinical development and CFTR-targeted programs, plus corporate strategy and timelines. According to the company, management intends to discuss clinical progress and their approach to developing medicines for cystic fibrosis.

Is Sionna Therapeutics (SION) presenting publicly at the Raymond James 2026 Biotech Innovation Symposium?

The company announced one-on-one investor meetings on April 14, 2026 but did not announce a public presentation. According to the company, management will participate specifically in one-on-one investor meetings at the symposium.

Will Sionna Therapeutics (SION) provide new clinical data at the Raymond James April 14, 2026 meetings?

The announcement did not state provision of new clinical data at the April 14, 2026 meetings. According to the company, management will participate in one-on-one investor meetings to discuss their cystic fibrosis programs and strategy.

Where and when is the Raymond James 2026 Biotech Innovation Symposium that Sionna (SION) will attend?

The Raymond James 2026 Biotech Innovation Symposium takes place in mid-April, with Sionna meetings on April 14, 2026. According to the company, management will hold one-on-one investor meetings during the event to discuss clinical programs.